CN Patent

CN113288905A — 含多替拉韦钠、拉米夫定和富马酸诺福韦酯的药物组合物

Assigned to Shijiazhuang Lonzeal Pharmaceutical Co ltd · Expires 2021-08-24 · 5y expired

What this patent protects

本发明涉及药物制剂技术领域，提出了一种含多替拉韦及其盐、拉米夫定、替诺福韦及其前药的药物组合物，通过将多替拉韦钠、拉米夫定和富马酸诺福韦酯分别单独制粒后再压片，制成单层溶蚀片。通过上述技术方案，不仅解决了替诺福韦因与多替拉韦不相容而产生降解的问题保证药品的稳定性，还解决了现有技术中双层片剂工艺复杂、设备要求高、产率低的问题。

USPTO Abstract

本发明涉及药物制剂技术领域，提出了一种含多替拉韦及其盐、拉米夫定、替诺福韦及其前药的药物组合物，通过将多替拉韦钠、拉米夫定和富马酸诺福韦酯分别单独制粒后再压片，制成单层溶蚀片。通过上述技术方案，不仅解决了替诺福韦因与多替拉韦不相容而产生降解的问题保证药品的稳定性，还解决了现有技术中双层片剂工艺复杂、设备要求高、产率低的问题。

Drugs covered by this patent

Patent Metadata

Patent number
CN113288905A
Jurisdiction
CN
Classification
—
Expires
2021-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Shijiazhuang Lonzeal Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.